CLOs on the Move

Eli Lilly

www.lilly.com

 
Lilly makes medicines that help people live longer, healthier, more active lives. We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people. We make medicines that help people live longer, ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.lilly.com
  • 1 Lilly Corporate Ctr
    Indianapolis, IN USA 46285
  • Phone: 317.276.2000

Executives

Name Title Contact Details
Sean Krispinsky
 Associate Vice President, Assistant General Counsel - Litigation, Legal Policy and Strategy Profile
Dipa Patel
 Associate Vice President - Assistant General Patent Counsel, Late Stage Key Products Profile
Erik Axelson
 Associate Vice President, Assistant General Counsel, BD Legal Profile
Brenda Danek
 Associate Vice President - Assistant General Patent Counsel, IP Litigation Profile
Peter Schutzel
 Senior Vice President & Deputy General Counsel Profile

Similar Companies

Ascend Laboratories

Ascend Laboratories is a Montvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ono Pharma USA Inc

Ono Pharma USA Inc is a Lawrence Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stone and Magnanini

Stone & Magnanini is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Directorie

Directories team of high-level marketing can-do-it-alls seamlessly join your team, dig in and get things done.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.